Compliance packaging to benefit from healthcare reform

Packaging that promotes patient compliance with drug regimens may be one area that gets additional attention as a result of healthcare reform. Further development and use of such packaging will, of course, be another driver of drug costs, but it may net a decrease in the overall cost of healthcare.

Use of compliance packaging may in particular grow for cold chain products, says one respondent to a late-September survey by Healthcare Packaging. Another cites clinical trials: "Our customers are usually willing to pay more for compliance packaging features if they are crucial to the particular study."

One survey-taker expresses concern that compliance features could impact the sterility and  integrity of drug products.

- see the article

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.